Recap Hey guys! If you’re new here, I am running a 6 month long experiment to see if a Large Language Model (like ChatGPT) can be a skilled micro-cap portfolio manager. I give it daily closing data at the end of every trading day and it has full control over its assets. Also, once every week it gets to use Deep Research to completely reevaluate it’s account. Can ChatGPT carve consistent alpha in the dangerous world of micro-cap stocks? Lets find out. Overview Despite a heavy drawdown on Monday, the portfolio recovered to just under 30 percent overall. The performance was mainly driven by ATYR, which now represents about 30 percent of total capital. AXGN gained 9 percent on the 26th, softening the hit from ATYR. IINN continued its downward trend, and ABEO fell 5.66 percent over the past five days. Current Portfolio ticker  shares  buy price  cost basis  stop loss ABEO     4.0       5.77       23.08        6.0 ATYR     8.0       5.09       40.72        4.2 IINN    10.0       1.25       12.50        1.0 AXGN     2.0      14.96       29.92       12.0 Cash: $15.08 Performance Graph Metrics: [ Risk & Return ] Max Drawdown:                             -7.11%   on 2025-07-11 Sharpe Ratio (period):                    1.2096 Sharpe Ratio (annualized):                2.8468 Sortino Ratio (period):                   2.1630 Sortino Ratio (annualized):               5.0906 [ CAPM vs Benchmarks ] Beta (daily) vs ^GSPC:                    2.0582 Alpha (annualized) vs ^GSPC:             150.40% R² (fit quality):                          0.173     Obs: 43 Note: Short sample and/or low R² — alpha/beta may be unstable. [ Snapshot ] Latest ChatGPT Equity:           $        129.22 $100.0 in S&P 500 (same window): $        104.11 Cash Balance:                    $         15.08 Portfolio Review Portfolio Review To see the full report: Click Here Click Here Updated Portfolio Thesis Summary (Post-Trade) Updated Portfolio Thesis Summary (Post-Trade) Keep / No Change Keep / No Change ABEO — hold 4 shares; stop $6.00. Thesis intact: gene therapy launch progressing; company well-capitalized. Already in profit; waiting for commercialization milestones.AXGN — hold 2 shares; stop raised to $13.00 (from $12.00). Despite FDA delay, fundamentals (revenue growth, approaching profitability) support holding through Dec 5 PDUFA; tighter stop manages risk during the wait. ABEO — hold 4 shares; stop $6.00. Thesis intact: gene therapy launch progressing; company well-capitalized. Already in profit; waiting for commercialization milestones. ABEO AXGN — hold 2 shares; stop raised to $13.00 (from $12.00). Despite FDA delay, fundamentals (revenue growth, approaching profitability) support holding through Dec 5 PDUFA; tighter stop manages risk during the wait. AXGN Dec 5 PDUFA Add to Existing Position Add to Existing Position ATYR — buy +3 (to 11 total); stop $4.20. High conviction in efzofitimod Phase 3 potential; now the largest holding (~$59). Positive setup (completed enrollment, strong scientific rationale, limited competition). Size remains modest and acknowledges gap risk. ATYR — buy +3 (to 11 total); stop $4.20. High conviction in efzofitimod Phase 3 potential; now the largest holding (~$59). Positive setup (completed enrollment, strong scientific rationale, limited competition). Size remains modest and acknowledges gap risk. ATYR Exit / Trim Positions Exit / Trim Positions IINN — sell 10 (exit). Catalyst ($22.5M order) realized; momentum faded; dilution risk. Redeploy ~$11 to higher-impact ideas (ATYR, FBIO). IINN — sell 10 (exit). Catalyst ($22.5M order) realized; momentum faded; dilution risk. Redeploy ~$11 to higher-impact ideas (ATYR, FBIO). IINN Initiate New Position Initiate New Position FBIO — buy 4 @ $2.58; stop $2.00. Near-term catalyst: Sept 30 FDA decision on CUTX-101 (potential PRV worth ~$100M+), which could drive a re-rating. Diversified assets cushion downside vs. single-asset risk. ($10, ~7–8% of portfolio); liquidity adequate (avg volume >300K). FBIO — buy 4 @ $2.58; stop $2.00. Near-term catalyst: Sept 30 FDA decision on CUTX-101 (potential PRV worth ~$100M+), which could drive a re-rating. Diversified assets cushion downside vs. single-asset risk. ($10, ~7–8% of portfolio); liquidity adequate (avg volume >300K). FBIO Sept 30 Notes Notes No other new positions added. OKYO and GENK were considered but not added due to timing and cash constraints. No other new positions added. OKYO and GENK were considered but not added due to timing and cash constraints. OKYO GENK My Thoughts FBIO has shown strong momentum with a 61 percent gain over the past six months and appears to be a solid option for diversification. Cutting IINN was the right move, as it continues to burn about 10 million dollars annually and the market shows no confidence even with a potential 22.5 million dollar deal. Doubling down on ATYR looks extremely risky; having a pure binary catalyst at 30 percent of the portfolio is already oversized, and increasing exposure further could create major downside risk, even if deep research reports have always remained bullish. This project is purely educational and research-focused. Nothing here should be taken as financial advice. Full disclaimer: Here Here GitHub Page and Email: GitHub Page and Email: To see past deep research reports and summaries: Click Here Click Here Have a question? Check out: Q&A Q&A If you’re curious about the code, prompts, graphing, etc. the GitHub page is: ChatGPT-Micro-Cap-Experiment. ChatGPT-Micro-Cap-Experiment If you have any suggestions or advice, Gmail is : nathanbsmith.business@gmail.com nathanbsmith.business@gmail.com

Keep

GitHub

Can ChatGPT Outperform the Market? Week 9

About Author

Comments

TOPICS

THIS ARTICLE WAS FEATURED IN

Related Stories

Can ChatGPT Outperform the Market? A Finance Nerd's Quest to Find Out

The Noonification: How Often Do NFTs Pass The Howey Test? (1/13/2023)

Darwin's Hybrid Intelligence to Align AI & Human Goals for Startups & VCs

The Noonification: White Man (11/26/2022)

The Noonification: The Metaverse is a Sh*tshow (11/2/2022)

100 Days of AI Day 1: From Newsletter to Podcast, Leveraging AI for Audio Transformation

Can ChatGPT Outperform the Market? A Finance Nerd's Quest to Find Out

The Noonification: How Often Do NFTs Pass The Howey Test? (1/13/2023)

Darwin's Hybrid Intelligence to Align AI & Human Goals for Startups & VCs

The Noonification: White Man (11/26/2022)

The Noonification: The Metaverse is a Sh*tshow (11/2/2022)

100 Days of AI Day 1: From Newsletter to Podcast, Leveraging AI for Audio Transformation

Light-Mode

Classic

Newspaper

Minty

Dark-Mode

Neon Noir

Minty

HN StartUps